Mark Stanley Berger

Filings by Mark Stanley Berger span 2 companies, the busiest being Genprex, Inc. and Actinium Pharmaceuticals, Inc. We count 9 filings; the first trade dates from 6 March 2018 and the latest from 27 February 2026.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The latest filing, published on 27 February 2026, reports a share grant of €12k in Genprex, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.